

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Vodis Pharmaceuticals Inc.** (the "Issuer").

Trading Symbol: **VP**

Number of Outstanding Listed Securities: **79,239,504**

Date: **September 4, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On January 31, 2020, the Issuer was issued a Standard Cultivation and Standard Processing Licence from Health Canada at its 12,000 sqft indoor facility in Delta, British Columbia.

Since receiving the licences, the Issuer has commenced its licensed operation with its acquired well-established and proven, proprietary live cultivars. In addition, the Issuer has accumulated an extensive seed collection that will serve as the foundation for future offerings and breeding. Jump-starting with proven, live mother plants significantly shortens the time horizon to bring unique cultivars to the Canadian craft cannabis market.

The Issuer is also exploring co-packaging and extract processing co-venture options to further accelerate its time to market and revenue.

The Issuer has received its Canada Revenue Agency (CRA) licence. In addition to the Health Canada licences, the CRA licence is required to conduct activities with cannabis.

During the month of August 2020, management of the Issuer continued with existing operational oversight, corporate governance and general operations.

2. Provide a general overview and discussion of the activities of management.

During the month of August 2020, management continued to search for business opportunities to enhance shareholder value.

Due to the COVID-19 pandemic, the Issuer is maintaining a minimal operating staff at its licensed Delta facility. The province of British Columbia has classified cannabis cultivation as an essential service. The Issuer is making every effort to maintain full operation in this difficult time.

On August 19, 2020, the Issuer issued a news release and announced that it has launched its new craft cannabis brand: Gnomestar Craft Cannabis and the harvest and hand-trim of its second crop, which consists of:

- 13.4 kg of Comatose Kush
- 12.8 kg of Meat Breath
- 16.1 kg of Red Congolese

On August 24, 2020, the Issuer issued a news release and provided update on the status of the filing of its annual financial statements and accompanying management's discussion and analysis for the financial year ended March 31, 2020 (the "Annual Filings"), and the filing of its financial statements for the three months ended June 30, 2020 and accompanying management's discussion and analysis (the "Q1 Filing") which were required to be filed by the scheduled due date of July 29, 2020, and August 29, 2020, as required by National Instrument 51-102. The Issuer is relying on BC Instrument 51-517 which extends the filing deadline by 45 days. The Company is continuing to work diligently and expeditiously with its auditors to file the Annual Filings by no later than September 12, 2020, and the Q1 Filings by no later than October 13, 2020.

The above mentioned announcements can be viewed under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website (www.thecse.ca).

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report during the month of August 2020.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report during the month of August 2020.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report during the month of August 2020.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report during the month of August 2020.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report during the month of August 2020.

8. Describe the acquisition of new customers or loss of customers.

None to report during the month of August 2020.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report during the month of August 2020.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of August 2020.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report during the month of August 2020.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of August 2020.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report during the month of August 2020.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
No securities were issued during the month of August 2020.			

15. Provide details of any loans to or by Related Persons.

None to report during the month of August 2020.

16. Provide details of any changes in directors, officers or committee members.

None to report during the month of August 2020.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Trends and risks which may impact the Issuer are disclosed in the Issuer's Interim Management's Discussion and Analysis dated March 2, 2020, and the Listing Statement dated August 28, 2014, which are available under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website (www.thecse.ca).

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 4, 2020.

Mark Lotz

Name of Director or Senior
Officer

/s/ "Mark Lotz"

Signature

CEO, CFO & Director

Official Capacity

Issuer Details Name of Issuer Vodis Pharmaceuticals Inc.	For Month End August 2020	Date of Report YY/MM/DD 2020 / 09 / 04
Issuer Address 8788 River Road		
City/Province/Postal Code Delta, BC V4G 1B5	Issuer Fax No. (604) 648-9568	Issuer Telephone No. 1(604) 880-6546
Contact Name Mark Lotz	Contact Position CEO, CFO, Director	Contact Telephone No. 1(604) 880-6546
Contact Email Address mark@vodis.ca	Web Site Address www.vodis.ca	